CD19 and lymphoma: Similar to our findings, a study of CD19 CAR-T cells with both VEN and S63845 in vitro demonstrated that concurrent treatment of lymphoma cells with BH3 mimetic + CAR-T leads to significant toxicity of the BH3 mimetic on CAR-T cells, and pre-treatment with the BH3 mimetic followed by CAR-T cells avoided this toxicity (75).